Haleon

Haleon and Brightseed have formed a strategic collaboration to utilize Brightseed's Forager® AI platform for discovering plant-based small molecules with potential health benefits.

Pfizer has sold its remaining 7.3% stake in consumer healthcare company Haleon for $3.3 billion through a secondary offering and share repurchase agreement, marking its complete exit from the UK-based firm.

• The FDA has approved Johnson & Johnson's Tremfya for moderately to severely active Crohn's disease, marking its fourth indication in the US based on robust data from phase III GALAXI and GRAVITI studies. • Novartis received FDA approval for Fabhalta to treat C3 glomerulopathy, becoming the first and only drug approved to address the underlying cause of this ultra-rare progressive kidney disease. • AstraZeneca announced plans to acquire Belgium-based EsoBiotec for up to $1 billion, while Sanofi is purchasing Dren Bio's DR-0201 for $600 million upfront to strengthen its immunology pipeline.

• Pfizer has engaged Goldman Sachs to explore the potential sale of its hospital drugs unit, which generates approximately $500 million in EBITDA and focuses on antibiotics and sterile injectables. • The hospital drugs unit, established following Pfizer's $17 billion acquisition of Hospira in 2015, is being evaluated for divestiture amid pressure from activist investor Starboard Value to streamline operations. • This strategic move follows Pfizer's recent $3.26 billion stake sale in Haleon and comes as the company seeks to reduce its $61.5 billion long-term debt while responding to criticism over acquisition strategies.